CLOs on the Move

drchrono

www.drchrono.com

 
drchrono is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.drchrono.com
  • 1001 N. Rengstorff Avenue Suite 200
    Mountain View, CA USA 94043
  • Phone: 844.569.8628

Executives

Name Title Contact Details

Similar Companies

Southeastern Urological Center PA

Southeastern Urological Center PA is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Tallahassee, FL. To find more information about Southeastern Urological Center PA, please visit www.seuc.com

Biological Test Center

Biological Test Center is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

National Decision Support Company

NDSC`s solutions are widely adopted and in use across the entire healthcare provider market in all 50 states and Europe. Organizations ranging from large, multi-state, integrated delivery networks to standalone ambulatory care settings, caregivers trust NDSC CareSelect™ platform to manage and track the actionable delivery of thousands of evidence-based guidelines.

FTI Healthcare

FTI Healthcare is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSig Technologies

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.